<!DOCTYPE html>
<html>

<head>
    <title>Methotrexate Product Monograph</title>
    <meta charset="UTP-8">
    <meta name="viewport" content ="width=device-width, initial-scale=1.0">
    <link rel ="stylesheet" type="text/css" href="styles.css">
    <!--<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lato">-->
</head>

<body>

    <nav id="navbar">
        <header>Methotrexate Product Monograph</header>
        <a class="nav-link" href="#indications">Indications</a>
        <a class="nav-link" href="#mechanism_of_action">Mechanism of Action</a>
        <a class="nav-link" href="#dosing_and_administration">Dosing and Administration</a>
        <a class="nav-link" href="#adverse_effects">Adverse Effects</a>
        <a class="nav-link" href="#drug_interactions">Drug Interactions</a>
        <a class="nav-link" href="#contraindications">Contraindications</a>
        <a class="nav-link" href="#resources">Resources</a>
    </nav>

    <main id="main-doc">

        <section id="indications" class="main-section">
            <header>Indications</header>

            <p>Disease modifying antirheumatic drug (DMARD) for treatment of:</p>
            <ul>
                <li>Rheumatoid Arthritis</li>
                <li>Psoriatic arthritis</li>
            </ul>

            <p>Chemotherapy for various forms of cancer including:</p>
            <ul>
                <li>Breast cancer</li>
                <li>Leukemia</li>
                <li>Gastric cancer</li>
                <li>Bladder cancer</li>
                <li>Cancer of bone</li>
            </ul>
        </section>
        
        <section id="mechanism_of_action" class="main-section">
            <header>Mechanism of Action</header>  
            <p>Inhibits dihydrofolate reductase thereby preventing DNA syntehsis, repair, and cell replication.
                Dihydrofolate reductase converts folic acid to tetrahydrofolate, which is required for DNA synthesis.
                Actively replicating cells such as cancer cells, bone marrow, and intestinal cells are more sensitive to this effect.
            </p>
        </section>

        <section id="dosing_and_administration" class="main-section">
            <header>Dosing and Administration</header>

            <table>
                <tr>
                    <th>Indication</th>
                    <th>Dosage Regimen</th>
                    <th>Maximum Dose</th>
                </tr>
                <tr>
                    <td>Rheumatoid Arthritis</td>
                    <td>
                        <p>PO: 10-15 mg weekly or</p>
                        <p>SC/IM: 10-25 mg weekly</p>
                    </td>
                    <td>
                        <p>PO: 25 mg/week</p>
                        <p>SC/IM: 30 mg/week</p>
                    </td>
                </tr> 
                <tr style="background-color: rgb(238, 236, 236);">
                    <td>Psoriatic Arthritis</td>
                    <td>
                        <p>PO: 10-25 mg weekly or 2.5mg Q12H for 3 doses</p>
                        <p>SC/IM/IV: 10-25 mg weekly</p>
                    </td>
                    <td>PO/SC/IM/IV: 30 mg/week</td>
                </tr>
                <tr>
                    <td>Cancer</td>
                    <td>Various weight- and BSA-based dosing regimens</td>
                    <td>Dependent on type of cancer</td>
            </table>
            <code>
                <p><strong>Abbreviations</strong></p>
                <p>PO: by mouth; SC: subcutaneous; IM: intramuscular; IV: intravenous; Q12H: every 12 hours; BSA: Body Surface Area.</p>
            </code>
        </section>

        <section id="adverse_effects" class="main-section">
            <header>Adverse Effects</header>
            <p>Most Common Adverse Reactions</p>
            <ul>
                <li>Gastrointestinal: Nausea, vomiting, diarrhea, ulcerative stomatitis</li>
                <li>Hepatic: <code>elevated liver enzymes</code></li>
            </ul>
            <p>Less Common Adverse Reactions</p>
            <ul>
                <li>Central nervous system: headache, dizziness</li>
                <li>Other: leukopenia, alopecia</li>
            </ul>
        </section>

        <section id="drug_interactions" class="main-section">
            <header>Drug Interactions</header>
            <p>NSAIDs: reduce renal elimination of methotrexate.</p>
            <code>Unpredictable severe reactions including death</code>
            <p>Alcohol: may enhance hepatotoxic effect of methotrexate</p>
            <code>Limit alcohol consumption</code>
            <p>Ciprofloxacin: may increase serum concentration of methotrexate</p>
            <p>Proton pump inhibitrs: may increase serum concentration of methotrexate</p>
            <p>Tacrolimus/Cyclosporine: may enhance toxic immunosuppresant effects of both drugs</p>
        </section>

        <section id="contraindications" class="main-section">
            <header>Contraindications</header>
            <p>Pregnancy: may cause <code>fetal death, abortion, or birth defects.</code></p>
            <p>Breastfeeding: potential for serious adverse reactions in breastfed infants.</p>
            <p>Alcoholic liver disease or other chronic liver disease.</p>
            <p>Immunodeficiency syndromes</p>
            <p>Blood dyscrasias including leukopenia, thrombocytopenia, significant anemia, and bone marrow hypoplasia</p>
        </section>
        
        <section id="resources" class="main-section">
            <header>Resources</header>
            <p><a target="_blank" href="https://online.lexi.com/">Lexicomp</a>: Methotrexate</p>
            <p><a target="_blank" href="https://www.myrxtx.ca/">Canadian Pharmacists Association RxTx</a>: Methotrexate/Methotrexate Sodium CPhA Monograph</p>
        </section>

        <a id="back_to_top" href="#main-doc"><button>Back to Top</button></a>
    </main>

</body>

</html>